BRIDGEBIO PHARMA, INC.

BBIO · NASDAQ

Pharmaceutical Preparation Manufacturing · US

BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio's pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.

Market Data

Price $74.33 +8.69 (+13.24%)

Market Cap$12.73B

P/E Ratio—

EPS$—

52W High$84.94

52W Low$28.33

Beta1.24

Data from Finnhub · Updated Mar 10, 2026